Cargando…
Efficacy and safety of Lenzumestrocel (Neuronata-R® inj.) in patients with amyotrophic lateral sclerosis (ALSUMMIT study): study protocol for a multicentre, randomized, double-blind, parallel-group, sham procedure-controlled, phase III trial
BACKGROUND: A single cycle (two repeated treatments) with intrathecal autologous bone marrow-derived mesenchymal stem cells (BM-MSCs, 26-day interval) showed safety and provided therapeutic benefit lasting 6 months in patients with ALS but did not demonstrate long-term efficacy. This phase III clini...
Autores principales: | Nam, Jae-Yong, Lee, Tae Yong, Kim, Kwijoo, Chun, Sehwan, Kim, Min Sung, Shin, Jin-Hong, Sung, Jung-Joon, Kim, Byoung Joon, Kim, Byung-Jo, Oh, Ki-Wook, Kim, Kyung Suk, Kim, Seung Hyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115933/ https://www.ncbi.nlm.nih.gov/pubmed/35585556 http://dx.doi.org/10.1186/s13063-022-06327-4 |
Ejemplares similares
-
Long-term survival benefits of intrathecal autologous bone marrow-derived mesenchymal stem cells (Neuronata-R®: lenzumestrocel) treatment in ALS: Propensity-score-matched control, surveillance study
por: Nam, Jae-Yong, et al.
Publicado: (2023) -
Basic Research as the Top Priority for INJ
por: Lee, Tack
Publicado: (2016) -
An analysis of variants in TARDBP in the Korean population with amyotrophic lateral sclerosis: comparison with previous data
por: Sung, Wonjae, et al.
Publicado: (2023) -
Four New Species of Amanita in Inje County, Korea
por: Cho, Hae Jin, et al.
Publicado: (2015) -
Amyotrophic Lateral Sclerosis Is Associated with Hypolipidemia at the Presymptomatic Stage in Mice
por: Kim, Sung-Min, et al.
Publicado: (2011)